Diadema Partners’s BridgeBio Pharma BBIO Stock Holding History

Diadema Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-139,600	Closed	-$10.7M	–	154
2025 Q4	$10.7M	Buy	139,600 +8,200	+6%	+$538K	1.84%	15
2025 Q3	$6.82M	Hold	131,400	–	–	1.75%	16
2025 Q2	$5.67M	Hold	131,400	–	–	1.73%	18
2025 Q1	$4.54M	Buy	131,400 +31,400	+31%	+$1.06M	1.19%	23
2024 Q4	$2.74M	Buy	+100,000	New	+$2.58M	1.18%	28

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Diadema Partners's BBIO Position: Q2 2026 in Review

Diadema Partners sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 85,311 shares — an estimated $6.34M sold.

Diadema Partners first reported a position in BBIO in Q4 2025 and held it in 2 quarters. The position peaked at $6.34M in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Diadema Partners reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Diadema Partners sold 85,311 BridgeBio Pharma shares in Q2 2026, an estimated $6.34M.
Diadema Partners first reported a position in BridgeBio Pharma in Q4 2025 and held it in 2 quarters.
Diadema Partners's BridgeBio Pharma position peaked at $6.34M in Q1 2026.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.